Analyst Sees 85% Upside for This Pharma Stock

ARVN scored a fresh "overweight" rating from Cantor Fitzgerald

Aug 6, 2019 at 2:33 PM
facebook twitter linkedin


The shares of biopharmaceutical concern Arvinas Inc (NASDAQ:ARVN) took a spill -- along with most of the stock market -- yesterday, as traders panned the company's quarterly earnings report. However, analysts at Cantor Fitzgerald aren't worried, initiating coverage of ARVN stock with an "overweight" rating and $42 price target -- nearly double yesterday's close of $22.75.

The analysts said Arvinas "is a leader in [the] underappreciated field of targeted protein degradation," and upcoming clinical data releases could be a boon for the shares. More specifically, Cantor waxed optimistic on the company's PROTAC platform, which "could emerge as a game-changing new modality," as well as its ARV-110 treatment, which could have "blockbuster potential in prostate cancer."

Since touching a record low of $10.19 on Dec. 21, ARVN stock has more than doubled, embarking on a series of higher highs and lows. The equity ultimately peaked at $28.25 on July 26, before pulling back to test its 80-day moving average. At last check, the shares were up 3.9% to trade at $23.64 -- a roughly 50% premium to ARVN's September initial public offering (IPO) price of $16.

ARVN stock chart aug 6

Should the security extend its quest for higher highs, a short squeeze could certainly add fuel to the fire. Short interest shot 21% higher during the past two reporting periods, and now accounts for more than 6% of ARVN's total available float. At the equity's average pace of trading, it would take shorts nearly a week to buy back their bearish bets.

In addition, there's room on the bullish bandwagon for more analysts. The current consensus 12-month price target on Arvinas shares is just $25.25 -- representing a slim 5.9% premium to the stock's current perch. Should the pharma stock resume its recent journey to all-time highs, a batch of price-target hikes could lure more buyers to the table.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners